查看購物車
  • Simplified Chinese
  • English
封面
市場調查報告書
商品編碼
1722667

2025 年至 2033 年阿黴素市場應用、配銷通路和地區報告

Doxorubicin Market Report by Application, Distribution Channel, and Region 2025-2033
出版日期: | 出版商: IMARC | 英文 142 Pages | 商品交期: 2-3個工作天內

價格

2024 年全球阿黴素市場規模達 13.3 億美元。展望未來， IMARC Group預計到 2033 年市場規模將達到 21.3 億美元，2025-2033 年期間的成長率 (CAGR) 為 5.06%。

阿黴素（DOX）是一種用於治療癌症化療過程中的通用藥物。它以注射液或冷凍乾燥粉末形式經由周邊插入中心靜脈導管（PICC）或中心靜脈導管（CVC）進行靜脈給藥。靜脈注射後，DOX 被酵素迅速消除並在血漿中發生水解分解。它用於治療多種類型的癌症，包括乳腺癌、膀胱癌、卡波西氏肉瘤、淋巴瘤、威爾姆斯腫瘤、非何杰金氏淋巴瘤和急性淋巴細胞白血病。

阿黴素市場趨勢：

癌症發生率的上升是推動全球阿黴素市場發展的主要因素。這導致 DOX 與其他化療藥物合併使用來治療各種癌症的情況越來越多。除此之外，對微創（MI）手術的需求不斷成長以及無法接受重大手術的老年人口不斷增加，導致人們越來越傾向於使用 DOX 作為癌症治療療法的一部分。各國政府也在實施舉措，支持臨床腫瘤學的技術進步，包括靜脈注射免費治療和用於片上生化分析的數位微流體技術。他們也正在加強對癌症治療的宣傳計畫。因此，對 DOX 的需求大幅增加。此外，研究人員還在臨床試驗上投入了大量資金，以開發技術先進的 DOX 配方。此外，預計未來幾年將越來越多的併購以及針對 DOX 先進形式的臨床試驗的合作將為市場帶來積極的前景。

本報告回答的關鍵問題

  • 阿黴素市場有多大？阿黴素市場未來前景如何？
  • 推動阿黴素市場發展的關鍵因素有哪些？
  • 哪個地區佔據阿黴素最大的市佔率？
  • 全球阿黴素市場領先的公司有哪些？

目錄

第1章：前言

第2章：範圍與方法

  • 研究目標
  • 利害關係人
  • 資料來源
    • 主要來源
    • 次要來源
  • 市場評估
    • 自下而上的方法
    • 自上而下的方法
  • 預測方法

第3章：執行摘要

第4章：簡介

  • 概述
  • 主要行業趨勢

第5章：全球阿黴素市場

  • 市場概覽
  • 市場表現
  • COVID-19的影響
  • 市場預測

第6章：市場區隔：依應用

  • 乳癌
  • 卵巢癌
  • 多發骨髓瘤
  • 卡波西氏肉瘤
  • 白血病
  • 骨肉瘤
  • 子宮內膜癌
  • 其他

第7章：市場區隔：按配銷通路

  • 醫院和零售藥局
  • 網路商店
  • 其他

第8章：市場區隔：依地區

  • 北美洲
    • 美國
    • 加拿大
  • 亞太
    • 中國
    • 日本
    • 印度
    • 韓國
    • 澳洲
    • 印尼
    • 其他
  • 歐洲
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙
    • 俄羅斯
    • 其他
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 其他
  • 中東和非洲
    • 市場區隔：依國家

第9章：SWOT分析

  • 概述
  • 優勢
  • 弱點
  • 機會
  • 威脅

第 10 章：價值鏈分析

第 11 章：波特五力分析

  • 概述
  • 買家的議價能力
  • 供應商的議價能力
  • 競爭程度
  • 新進入者的威脅
  • 替代品的威脅

第 12 章：價格分析

第 13 章：競爭格局

  • 市場結構
  • 關鍵參與者
  • 關鍵參與者簡介
    • Accord Healthcare Ltd. (Intas Pharmaceuticals Limited)
    • Baxter International Inc.
    • Cadila Pharmaceuticals
    • Cipla Inc.
    • Hikma Pharmaceuticals PLC
    • Meiji Holdings Co. Ltd.
    • Novartis AG
    • Pfizer Inc.
Product Code: SR112025A5677

The global doxorubicin market size reached USD 1.33 Billion in 2024. Looking forward, IMARC Group expects the market to reach USD 2.13 Billion by 2033, exhibiting a growth rate (CAGR) of 5.06% during 2025-2033.

Doxorubicin (DOX) is a generic medicine used in the process of chemotherapy for treating cancer. It is used as an injection solution or in lyophilized powder form to intravenously administer through peripherally inserted central line catheter (PICC) or central venous catheter (CVC). DOX is rapidly eliminated by enzymes and encounters hydrolytic degradation in plasma after intravenous administration. It is used to treat several types of cancer, including breast cancer, bladder cancer, Kaposi's sarcoma, lymphoma, Wilms' tumor, non-Hodgkin's lymphoma, and acute lymphocytic leukemia.

Doxorubicin Market Trends:

The increasing prevalence of cancer is primarily driving the global doxorubicin market. This has resulted in the growing use of DOX in combination with other chemotherapeutic agents to treat a variety of carcinomas. Besides this, the rising demand for minimally invasive (MI) surgical procedures and the growing geriatric population who cannot undergo significant surgeries have led to the growing preference for DOX as part of the cancer treatment therapies. Governments of different countries are also implementing initiatives to support technological advancements in clinical oncology, including intravenous free therapy and digital microfluidics for on-chip biochemical analysis. They are also increasing awareness programs for the treatment of cancer. As a result, there has been a significant increase in the demand for DOX. Furthermore, researchers are spending a considerable amount on clinical trials to develop technologically advanced DOX formulations. Moreover, the growing number of mergers and acquisitions as well as partnerships for clinical trials with advanced forms of DOX is expected to create a positive outlook for the market in the coming years.

Key Market Segmentation:

Breakup by Application:

  • Breast Cancer
  • Ovarian Cancer
  • Multiple Myeloma
  • Kaposi Sarcoma
  • Leukemia
  • Bone Sarcoma
  • Endometrial Cancer
  • Others

Breakup by Distribution Channel:

  • Hospital and Retail Pharmacies
  • Online Stores
  • Others

Breakup by Region:

  • North America
  • United States
  • Canada
  • Asia-Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Indonesia
  • Others
  • Europe
  • Germany
  • France
  • United Kingdom
  • Italy
  • Spain
  • Russia
  • Others
  • Latin America
  • Brazil
  • Mexico
  • Others
  • Middle East and Africa

Competitive Landscape:

The competitive landscape of the industry has also been examined along with the profiles of the key players being Accord Healthcare Ltd. (Intas Pharmaceuticals Limited), Baxter International Inc., Cadila Pharmaceuticals, Cipla Inc., Hikma Pharmaceuticals PLC, Meiji Holdings Co. Ltd., Novartis AG and Pfizer Inc.

Key Questions Answered in This Report

  • 1.How big is the doxorubicin market?
  • 2.What is the future outlook of doxorubicin market?
  • 3.What are the key factors driving the doxorubicin market?
  • 4.Which region accounts for the largest doxorubicin market share?
  • 5.Which are the leading companies in the global doxorubicin market?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Doxorubicin Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Application

  • 6.1 Breast Cancer
    • 6.1.1 Market Trends
    • 6.1.2 Market Forecast
  • 6.2 Ovarian Cancer
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast
  • 6.3 Multiple Myeloma
    • 6.3.1 Market Trends
    • 6.3.2 Market Forecast
  • 6.4 Kaposi Sarcoma
    • 6.4.1 Market Trends
    • 6.4.2 Market Forecast
  • 6.5 Leukemia
    • 6.5.1 Market Trends
    • 6.5.2 Market Forecast
  • 6.6 Bone Sarcoma
    • 6.6.1 Market Trends
    • 6.6.2 Market Forecast
  • 6.7 Endometrial Cancer
    • 6.7.1 Market Trends
    • 6.7.2 Market Forecast
  • 6.8 Others
    • 6.8.1 Market Trends
    • 6.8.2 Market Forecast

7 Market Breakup by Distribution Channel

  • 7.1 Hospital and Retail Pharmacies
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Online Stores
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast
  • 7.3 Others
    • 7.3.1 Market Trends
    • 7.3.2 Market Forecast

8 Market Breakup by Region

  • 8.1 North America
    • 8.1.1 United States
      • 8.1.1.1 Market Trends
      • 8.1.1.2 Market Forecast
    • 8.1.2 Canada
      • 8.1.2.1 Market Trends
      • 8.1.2.2 Market Forecast
  • 8.2 Asia-Pacific
    • 8.2.1 China
      • 8.2.1.1 Market Trends
      • 8.2.1.2 Market Forecast
    • 8.2.2 Japan
      • 8.2.2.1 Market Trends
      • 8.2.2.2 Market Forecast
    • 8.2.3 India
      • 8.2.3.1 Market Trends
      • 8.2.3.2 Market Forecast
    • 8.2.4 South Korea
      • 8.2.4.1 Market Trends
      • 8.2.4.2 Market Forecast
    • 8.2.5 Australia
      • 8.2.5.1 Market Trends
      • 8.2.5.2 Market Forecast
    • 8.2.6 Indonesia
      • 8.2.6.1 Market Trends
      • 8.2.6.2 Market Forecast
    • 8.2.7 Others
      • 8.2.7.1 Market Trends
      • 8.2.7.2 Market Forecast
  • 8.3 Europe
    • 8.3.1 Germany
      • 8.3.1.1 Market Trends
      • 8.3.1.2 Market Forecast
    • 8.3.2 France
      • 8.3.2.1 Market Trends
      • 8.3.2.2 Market Forecast
    • 8.3.3 United Kingdom
      • 8.3.3.1 Market Trends
      • 8.3.3.2 Market Forecast
    • 8.3.4 Italy
      • 8.3.4.1 Market Trends
      • 8.3.4.2 Market Forecast
    • 8.3.5 Spain
      • 8.3.5.1 Market Trends
      • 8.3.5.2 Market Forecast
    • 8.3.6 Russia
      • 8.3.6.1 Market Trends
      • 8.3.6.2 Market Forecast
    • 8.3.7 Others
      • 8.3.7.1 Market Trends
      • 8.3.7.2 Market Forecast
  • 8.4 Latin America
    • 8.4.1 Brazil
      • 8.4.1.1 Market Trends
      • 8.4.1.2 Market Forecast
    • 8.4.2 Mexico
      • 8.4.2.1 Market Trends
      • 8.4.2.2 Market Forecast
    • 8.4.3 Others
      • 8.4.3.1 Market Trends
      • 8.4.3.2 Market Forecast
  • 8.5 Middle East and Africa
    • 8.5.1 Market Trends
    • 8.5.2 Market Breakup by Country
    • 8.5.3 Market Forecast

9 SWOT Analysis

  • 9.1 Overview
  • 9.2 Strengths
  • 9.3 Weaknesses
  • 9.4 Opportunities
  • 9.5 Threats

10 Value Chain Analysis

11 Porters Five Forces Analysis

  • 11.1 Overview
  • 11.2 Bargaining Power of Buyers
  • 11.3 Bargaining Power of Suppliers
  • 11.4 Degree of Competition
  • 11.5 Threat of New Entrants
  • 11.6 Threat of Substitutes

12 Price Analysis

13 Competitive Landscape

  • 13.1 Market Structure
  • 13.2 Key Players
  • 13.3 Profiles of Key Players
    • 13.3.1 Accord Healthcare Ltd. (Intas Pharmaceuticals Limited)
      • 13.3.1.1 Company Overview
      • 13.3.1.2 Product Portfolio
    • 13.3.2 Baxter International Inc.
      • 13.3.2.1 Company Overview
      • 13.3.2.2 Product Portfolio
      • 13.3.2.3 Financials
      • 13.3.2.4 SWOT Analysis
    • 13.3.3 Cadila Pharmaceuticals
      • 13.3.3.1 Company Overview
      • 13.3.3.2 Product Portfolio
    • 13.3.4 Cipla Inc.
      • 13.3.4.1 Company Overview
      • 13.3.4.2 Product Portfolio
      • 13.3.4.3 Financials
      • 13.3.4.4 SWOT Analysis
    • 13.3.5 Hikma Pharmaceuticals PLC
      • 13.3.5.1 Company Overview
      • 13.3.5.2 Product Portfolio
    • 13.3.6 Meiji Holdings Co. Ltd.
      • 13.3.6.1 Company Overview
      • 13.3.6.2 Product Portfolio
      • 13.3.6.3 Financials
      • 13.3.6.4 SWOT Analysis
    • 13.3.7 Novartis AG
      • 13.3.7.1 Company Overview
      • 13.3.7.2 Product Portfolio
      • 13.3.7.3 Financials
      • 13.3.7.4 SWOT Analysis
    • 13.3.8 Pfizer Inc.
      • 13.3.8.1 Company Overview
      • 13.3.8.2 Product Portfolio
      • 13.3.8.3 Financials
      • 13.3.8.4 SWOT Analysis

List of Figures

  • Figure 1: Global: Doxorubicin Market: Major Drivers and Challenges
  • Figure 2: Global: Doxorubicin Market: Sales Value (in Billion USD), 2019-2024
  • Figure 3: Global: Doxorubicin Market Forecast: Sales Value (in Billion USD), 2025-2033
  • Figure 4: Global: Doxorubicin Market: Breakup by Application (in %), 2024
  • Figure 5: Global: Doxorubicin Market: Breakup by Distribution Channel (in %), 2024
  • Figure 6: Global: Doxorubicin Market: Breakup by Region (in %), 2024
  • Figure 7: Global: Doxorubicin (Breast Cancer) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 8: Global: Doxorubicin (Breast Cancer) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 9: Global: Doxorubicin (Ovarian Cancer) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 10: Global: Doxorubicin (Ovarian Cancer) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 11: Global: Doxorubicin (Multiple Myeloma) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 12: Global: Doxorubicin (Multiple Myeloma) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 13: Global: Doxorubicin (Kaposi Sarcoma) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 14: Global: Doxorubicin (Kaposi Sarcoma) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 15: Global: Doxorubicin (Leukemia) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 16: Global: Doxorubicin (Leukemia) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 17: Global: Doxorubicin (Bone Sarcoma) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 18: Global: Doxorubicin (Bone Sarcoma) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 19: Global: Doxorubicin (Endometrial Cancer) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 20: Global: Doxorubicin (Endometrial Cancer) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 21: Global: Doxorubicin (Other Applications) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 22: Global: Doxorubicin (Other Applications) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 23: Global: Doxorubicin (Hospital and Retail Pharmacies) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 24: Global: Doxorubicin (Hospital and Retail Pharmacies) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 25: Global: Doxorubicin (Online Stores) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 26: Global: Doxorubicin (Online Stores) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 27: Global: Doxorubicin (Other Distribution Channels) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 28: Global: Doxorubicin (Other Distribution Channels) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 29: North America: Doxorubicin Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 30: North America: Doxorubicin Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 31: United States: Doxorubicin Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 32: United States: Doxorubicin Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 33: Canada: Doxorubicin Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 34: Canada: Doxorubicin Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 35: Asia-Pacific: Doxorubicin Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 36: Asia-Pacific: Doxorubicin Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 37: China: Doxorubicin Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 38: China: Doxorubicin Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 39: Japan: Doxorubicin Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 40: Japan: Doxorubicin Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 41: India: Doxorubicin Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 42: India: Doxorubicin Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 43: South Korea: Doxorubicin Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 44: South Korea: Doxorubicin Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 45: Australia: Doxorubicin Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 46: Australia: Doxorubicin Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 47: Indonesia: Doxorubicin Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 48: Indonesia: Doxorubicin Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 49: Others: Doxorubicin Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 50: Others: Doxorubicin Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 51: Europe: Doxorubicin Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 52: Europe: Doxorubicin Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 53: Germany: Doxorubicin Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 54: Germany: Doxorubicin Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 55: France: Doxorubicin Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 56: France: Doxorubicin Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 57: United Kingdom: Doxorubicin Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 58: United Kingdom: Doxorubicin Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 59: Italy: Doxorubicin Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 60: Italy: Doxorubicin Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 61: Spain: Doxorubicin Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 62: Spain: Doxorubicin Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 63: Russia: Doxorubicin Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 64: Russia: Doxorubicin Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 65: Others: Doxorubicin Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 66: Others: Doxorubicin Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 67: Latin America: Doxorubicin Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 68: Latin America: Doxorubicin Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 69: Brazil: Doxorubicin Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 70: Brazil: Doxorubicin Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 71: Mexico: Doxorubicin Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 72: Mexico: Doxorubicin Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 73: Others: Doxorubicin Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 74: Others: Doxorubicin Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 75: Middle East and Africa: Doxorubicin Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 76: Middle East and Africa: Doxorubicin Market: Breakup by Country (in %), 2024
  • Figure 77: Middle East and Africa: Doxorubicin Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 78: Global: Doxorubicin Industry: SWOT Analysis
  • Figure 79: Global: Doxorubicin Industry: Value Chain Analysis
  • Figure 80: Global: Doxorubicin Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: Doxorubicin Market: Key Industry Highlights, 2024 and 2033
  • Table 2: Global: Doxorubicin Market Forecast: Breakup by Application (in Million USD), 2025-2033
  • Table 3: Global: Doxorubicin Market Forecast: Breakup by Distribution Channel (in Million USD), 2025-2033
  • Table 4: Global: Doxorubicin Market Forecast: Breakup by Region (in Million USD), 2025-2033
  • Table 5: Global: Doxorubicin Market: Competitive Structure
  • Table 6: Global: Doxorubicin Market: Key Players